289 related articles for article (PubMed ID: 12485949)
21. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase.
Rivory LP; Bowles MR; Robert J; Pond SM
Biochem Pharmacol; 1996 Oct; 52(7):1103-11. PubMed ID: 8831730
[TBL] [Abstract][Full Text] [Related]
22. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase.
Satoh T; Hosokawa M; Atsumi R; Suzuki W; Hakusui H; Nagai E
Biol Pharm Bull; 1994 May; 17(5):662-4. PubMed ID: 7920428
[TBL] [Abstract][Full Text] [Related]
23. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity.
Hennebelle I; Terret C; Chatelut E; Bugat R; Canal P; Guichard S
Anticancer Drugs; 2000 Jul; 11(6):465-70. PubMed ID: 11001387
[TBL] [Abstract][Full Text] [Related]
24. Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
Oosterhoff D; Pinedo HM; van der Meulen IH; de Graaf M; Sone T; Kruyt FA; van Beusechem VW; Haisma HJ; Gerritsen WR
Br J Cancer; 2002 Sep; 87(6):659-64. PubMed ID: 12237777
[TBL] [Abstract][Full Text] [Related]
25. Crystal structure of the Geobacillus stearothermophilus carboxylesterase Est55 and its activation of prodrug CPT-11.
Liu P; Ewis HE; Tai PC; Lu CD; Weber IT
J Mol Biol; 2007 Mar; 367(1):212-23. PubMed ID: 17239398
[TBL] [Abstract][Full Text] [Related]
26. An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11.
Wierdl M; Tsurkan L; Hyatt JL; Edwards CC; Hatfield MJ; Morton CL; Houghton PJ; Danks MK; Redinbo MR; Potter PM
Cancer Gene Ther; 2008 Mar; 15(3):183-92. PubMed ID: 18188187
[TBL] [Abstract][Full Text] [Related]
27. Pharmacology of irinotecan.
Kuhn JG
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):39-42. PubMed ID: 9726089
[TBL] [Abstract][Full Text] [Related]
28. Rat kidney carboxylesterase. Cloning, sequencing, cellular localization, and relationship to rat liver hydrolase.
Yan B; Yang D; Brady M; Parkinson A
J Biol Chem; 1994 Nov; 269(47):29688-96. PubMed ID: 7961958
[TBL] [Abstract][Full Text] [Related]
29. Metabolism of CPT-11. Impact on activity.
Rivory LP
Ann N Y Acad Sci; 2000; 922():205-15. PubMed ID: 11193896
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of a new class of camptothecin derivatives, the long-chain fatty acid esters of 10-hydroxycamptothecin, as a potent prodrug candidate, and their in vitro metabolic conversion by carboxylesterases.
Takayama H; Watanabe A; Hosokawa M; Chiba K; Satoh T; Aimi N
Bioorg Med Chem Lett; 1998 Mar; 8(5):415-8. PubMed ID: 9871589
[TBL] [Abstract][Full Text] [Related]
31. Purification and characterization of two rat liver microsomal carboxylesterases (hydrolase A and B).
Morgan EW; Yan B; Greenway D; Petersen DR; Parkinson A
Arch Biochem Biophys; 1994 Dec; 315(2):495-512. PubMed ID: 7986098
[TBL] [Abstract][Full Text] [Related]
32. Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan.
Guemei AA; Cottrell J; Band R; Hehman H; Prudhomme M; Pavlov MV; Grem JL; Ismail AS; Bowen D; Taylor RE; Takimoto CH
Cancer Chemother Pharmacol; 2001 Apr; 47(4):283-90. PubMed ID: 11345644
[TBL] [Abstract][Full Text] [Related]
33. CPT-11 converting enzyme from rat serum: purification and some properties.
Tsuji T; Kaneda N; Kado K; Yokokura T; Yoshimoto T; Tsuru D
J Pharmacobiodyn; 1991 Jun; 14(6):341-9. PubMed ID: 1783980
[TBL] [Abstract][Full Text] [Related]
34. OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice.
Iusuf D; Ludwig M; Elbatsh A; van Esch A; van de Steeg E; Wagenaar E; van der Valk M; Lin F; van Tellingen O; Schinkel AH
Mol Cancer Ther; 2014 Feb; 13(2):492-503. PubMed ID: 24194565
[TBL] [Abstract][Full Text] [Related]
35. Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity.
Hyatt JL; Tsurkan L; Wierdl M; Edwards CC; Danks MK; Potter PM
Mol Cancer Ther; 2006 Sep; 5(9):2281-8. PubMed ID: 16985062
[TBL] [Abstract][Full Text] [Related]
36. Partial purification and characterization of an esterase acting on the anticancer pro-drugs, 7-ethylcamptothecin derivatives.
Fujita Y; Yaegashi T; Sawada S; Oyama H; Yoshimoto T; Tsuru D
Biol Pharm Bull; 1995 May; 18(5):648-52. PubMed ID: 7492976
[TBL] [Abstract][Full Text] [Related]
37. Determination of drug interactions occurring with the metabolic pathways of irinotecan.
Charasson V; Haaz MC; Robert J
Drug Metab Dispos; 2002 Jun; 30(6):731-3. PubMed ID: 12019202
[TBL] [Abstract][Full Text] [Related]
38. In vitro activation of irinotecan to SN-38 by human liver and intestine.
Ahmed F; Vyas V; Cornfield A; Goodin S; Ravikumar TS; Rubin EH; Gupta E
Anticancer Res; 1999; 19(3A):2067-71. PubMed ID: 10470149
[TBL] [Abstract][Full Text] [Related]
39. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.
Yoon KJ; Krull EJ; Morton CL; Bornmann WG; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2003 Nov; 2(11):1171-81. PubMed ID: 14617791
[TBL] [Abstract][Full Text] [Related]
40. Lessons learned from the irinotecan metabolic pathway.
Ma MK; McLeod HL
Curr Med Chem; 2003 Jan; 10(1):41-9. PubMed ID: 12570720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
